Cardiology Clinical Academic Group, St George's University Hospitals' NHS Foundation Trust and Molecular and Clinical Sciences Institute, St George's University of London, United Kingdom (C.M., G.F., M.P., B.G., J.W., B.E., J.B., G.P.-W., E.P. C.P., A.M., A.A., M.T., S.S., E.R.B., M.N.S.).
Department of Pathology, Royal Brompton and Harefield NHS Foundation Trust, Imperial College London, United Kingdom (J.L.R.).
Circulation. 2019 Apr 9;139(15):1786-1797. doi: 10.1161/CIRCULATIONAHA.118.037230.
Arrhythmogenic cardiomyopathy (ACM) is an inherited heart muscle disorder characterized by myocardial fibrofatty replacement and an increased risk of sudden cardiac death (SCD). Originally described as a right ventricular disease, ACM is increasingly recognized as a biventricular entity. We evaluated pathological, genetic, and clinical associations in a large SCD cohort.
We investigated 5205 consecutive cases of SCD referred to a national cardiac pathology center between 1994 and 2018. Hearts and tissue blocks were examined by expert cardiac pathologists. After comprehensive histological evaluation, 202 cases (4%) were diagnosed with ACM. Of these, 15 (7%) were diagnosed antemortem with dilated cardiomyopathy (n=8) or ACM (n=7). Previous symptoms, medical history, circumstances of death, and participation in competitive sport were recorded. Postmortem genetic testing was undertaken in 24 of 202 (12%). Rare genetic variants were classified according to American College of Medical Genetics and Genomics criteria.
Of 202 ACM decedents (35.4±13.2 years; 82% male), no previous cardiac symptoms were reported in 157 (78%). Forty-one decedents (41/202; 20%) had been participants in competitive sport. The adjusted odds of dying during physical exertion were higher in men than in women (odds ratio, 4.58; 95% CI, 1.54-13.68; P=0.006) and in competitive athletes in comparison with nonathletes (odds ratio, 16.62; 95% CI, 5.39-51.24; P<0.001). None of the decedents with an antemortem diagnosis of dilated cardiomyopathy fulfilled definite 2010 Task Force criteria. The macroscopic appearance of the heart was normal in 40 of 202 (20%) cases. There was left ventricular histopathologic involvement in 176 of 202 (87%). Isolated right ventricular disease was seen in 13%, isolated left ventricular disease in 17%, and biventricular involvement in 70%. Among whole hearts, the most common areas of fibrofatty infiltration were the left ventricular posterobasal (68%) and anterolateral walls (58%). Postmortem genetic testing yielded pathogenic variants in ACM-related genes in 6 of 24 (25%) decedents.
SCD attributable to ACM affects men predominantly, most commonly occurring during exertion in athletic individuals in the absence of previous reported cardiac symptoms. Left ventricular involvement is observed in the vast majority of SCD cases diagnosed with ACM at autopsy. Current Task Force criteria may fail to diagnose biventricular ACM before death.
致心律失常性右室心肌病(ARVC)是一种遗传性心肌疾病,其特征为心肌纤维脂肪替代和心脏性猝死(SCD)风险增加。最初被描述为右心室疾病,现在已经越来越被认为是一种双心室疾病。我们评估了一个大型 SCD 队列中的病理、遗传和临床关联。
我们调查了 1994 年至 2018 年间,全国心脏病理学中心收治的 5205 例连续 SCD 病例。由经验丰富的心脏病专家检查心脏和组织块。在进行全面的组织学评估后,202 例(4%)被诊断为 ARVC。其中,15 例(7%)在生前被诊断为扩张型心肌病(n=8)或 ARVC(n=7)。记录了既往症状、病史、死亡情况和参加竞技运动的情况。对 202 例 ARVC 死者中的 24 例(12%)进行了死后基因检测。根据美国医学遗传学与基因组学学院的标准对罕见的基因突变进行分类。
在 202 名 ARVC 死者中(35.4±13.2 岁;82%为男性),157 名(78%)没有先前的心脏症状。41 名死者(41/202;20%)是竞技运动员。与女性相比,男性在体力活动期间死亡的调整后几率更高(优势比,4.58;95%CI,1.54-13.68;P=0.006),与非运动员相比,竞技运动员的几率更高(优势比,16.62;95%CI,5.39-51.24;P<0.001)。生前被诊断为扩张型心肌病的死者无一例符合 2010 年工作组的明确标准。202 例死者中有 40 例(20%)心脏的大体外观正常。202 例死者中有 176 例(87%)存在左心室组织病理学受累。单纯右心室疾病占 13%,单纯左心室疾病占 17%,双心室受累占 70%。在整个心脏中,纤维脂肪浸润最常见的部位是左心室后基底(68%)和前外侧壁(58%)。对 24 例死者中的 6 例(25%)进行了 ARVC 相关基因的死后基因检测,发现了致病性变异。
由 ARVC 引起的 SCD 主要影响男性,最常发生在无先前报告的心脏症状的运动个体进行体力活动时。尸检诊断为 ARVC 的大多数 SCD 病例中都存在左心室受累。目前的工作组标准可能无法在死亡前诊断出双心室 ARVC。